Polyphor AG bags CHF19.3 in equity financing
Swiss Polyphor AG has strengthened its financial flexibility with an equity-linked financing.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1120 entries already.
Entries by Thomas Gabrielczyk
COVID-19: Siemens assay outperforms antibody tests from competitors
/in News/by Thomas GabrielczykIn a Public England Health study, Siemens Healthineers COV2T antibody test was the only assay found to meet both sensitivity and specificity requirements of the MHRA.
AMR: Big Pharma sets up US$1bn Fund
/in News/by Thomas GabrielczykAfter leaving the field of antimicrobials 20 years ago because other areas offered better returns, 23 pharma companies and the Novo Foundation have launched a US$1bn fund to fight antimicrobial […]
VarmX bags 32m in Series B round
/in News/by Thomas GabrielczykLeiden-based coagulant developer VarmX NV has closed a 32m Series B financing to push the Phase II development of VMX-C001, a venom-based modified recombinant Factor X.
APEIRON Biologics licences MaxCytes electroporation platform
/in News/by Thomas GabrielczykViennese APEIRON Biologics and MaxCyte Inc have entered into licensing agreement covering the use of Maxcytes electroporation platform for APN401 development.
Immatics launches US$250m Nasdaq-IPO
/in News/by Thomas GabrielczykAfter closing the business merging with blank check company Arya Sciences Acquisition Corp, Immatics Inc has been listed on Nasdaq.
New insulin formulation allows faster blood sugar management
/in News/by Thomas GabrielczykA new insulin formulation allows patients with diabetes to more quickly manage their blood sugar levels during mealtimes.
COVID-19: Lopinavir-ritonavir failed
/in News/by Thomas GabrielczykData from the UKs RECOVERY trial demonstrate there was no clinical benefit from use of lopinavir-ritonavir in hospitalised COVID-19 patients.
EC pledges 4.9bn to grant access to medicines
/in News/by Thomas GabrielczykUnder the Coronavirus Global Response Framework, the European Commission is allocating further 4.9bn to assure access to COVID-19 countermeasures for poor countries.
BioGeneration Ventures closes BGV IV Fund at 105m
/in News/by Thomas GabrielczykBioGeneration Ventures has closed its fourth VC fund for European start-ups (BGV IV) at 105m.